## The Product Datasheet-Formulation and Antibody Performance

The Antibody Society Webcast series – Antibody Validation #4

Dr. Jan Voskuil Director of Aeonian Biotech Ltd 2019

ANTI BODY SOCI . ETY

## What to look for when shopping around?

- Be convinced that your choice will meet your expectations.
- Performance must be consistent from purchase to purchase.
- Product ideally will still exist and remains available 10-20 years later!
- The Product Datasheet provides the clues:

#### Fixed parameters:

- Catalog number and batch/clone
  number
- Names and symbols of protein
- GeneID and/or SwissProt accession
- Host species and isotype
- Antigen & Epitope
- Purification method
- Formulation (buffer components)
- Amount (mg or ml)

#### Claims of performance:

- Application claims
- Titre in ELISA
- Positive controls (tissues; cell types; cell lines)
- Successful usage claims in literature
- Data confirming molecular integrity
- Data confirming no cross-reactivity to closely related proteins
- Negative controls
- Data confirming successful use in applications

ANTI

OD S

ТҮ

## What are the pitfalls to watch for?

Fixed parameters:

Shared Symbols. e.g.: OCT2 (SLC22A2, GeneID 6582 and POU2F2, GeneID 5452)

Renamed clones. e.g.: re-cloned hybridoma

Batch-to-batch inconsistency. e.g.: is next purchase from different animal or different purification

Aliquots from the same batch may differ in performance due to storage/handling history

Are you buying volumes or quantities?

Has the antibody been purified, and how? (e.g. NH<sub>3</sub>SO<sub>4</sub>-cut; Protein A; or antigen affinity)

Do you need a domain-specific or epitope-specific antibody?

In what formulation is the antibody offered (buffer components)?



### What are the pitfalls to watch for?

**Performance parameters:** 

Are the claimed applications supported by data (from literature or datasheet?)

Do the data presented comply with the science (example: is detection in correct cell compartment or tissue)

Are data presented fit-for-purpose? (wrong: FC on cell line; ICC staining entire cells; IHC with blurred stains)

Each application is demonstrated under different conditions (tested on peptide, protein, cell type, etc)

Is the antibody compared with another gold-standard one?

Has the antibody been tested on both expressing and non-expressing cells/tissues?

Has the antibody been tested on closely related proteins (from the same protein family)?

Are comparisons all done at the same time and at the same dilution/antibody concentration?

ANTI BODY SOCI . ETY

## Summary

- Vendor may provide evidence, but scientist must verify.
- Choose antibody shown fit for the assay type you need it for.
- Ensure the antibody works in the cell types you need it for.
- Selectivity (correct negatives) trumps specificity (correct positives)

Read more on the subject:

Voskuil (2017) The challenges with the validation of research antibodies. **F1000Res 6:161**.





# What antibody have I found?

The Antibody Society Webcast series – Antibody Validation #4

Anita Bardowski UCSD; SciCrunch

Jan Voskuil Aeonian Biotech

ANTI BODY SOCI ETY

#### Next Webcast in Antibody Validation: a 9-part series

| 1. | Andreas Pluckthun      | • | The different antibody formats                                  |
|----|------------------------|---|---|
| 2. | Glenn Begley           | : | Antibodies and the reproducibility crisis in biological science |
|    | Cecilia Williams       | : | The Erß story – is your antibody like this?                     |
| 3. | Jan Voskuil            | • | Beware the supplier OEM   |
|    | Andy Chalmers          | : | Finding antibodies in the Antibody Databases                    |
| 4. | Anita Bardowski        | : | Which antibody are you looking for? The RRID                    |
|    | Jan Voskuil            | : | Points to note on the supplier datasheets                       |
| 5. | Giovanna Roncador:     | • | Correct positive and negative controls in validation            |
| 6. | Aldrin Gomes           | • | Standard technology: "even" Western blots are non-trivial       |
|    | Jim Trimmer            | : | IHC issues in brain sciences                                    |
| 7. | Travis Hardcastle      | • | Cell KO technology  |
|    | Alejandra Solache      | : | Validating Antibodies with KO technology                        |
| 8. | Mike Taussig           | : | Validating antibodies using array technologies                  |
|    | Fridjhof Lund-Johansen | : | Mass spectroscopy for mass validation                           |
| 9. | Andrew Bradbury        | • | Why publish sequences?  |
|    | Andreas Pluckthun      | : | What are the coming alternatives ?                              |

## Validation of Commercial tool Antibodies

#### What antibody have I found?

The Antibody Society Webcast series – Antibody Validation #4

Presented by Anita Bandrowski and Jan Voskuil Produced and Directed by Simon L. Goodman Technical Assistance and Editing Fran Breden Writen by Simon Goodman https://www.antibodysociety.org/

ANTI BODY SOCI . ETY

#### Validation of Commercial Tool Antibodies

An Antibody Society Webcast series

Administrative Support: Dr. Fran Breden and Dr. Mini Muralidharan

Executive Director: Dr. Jan Reichert

This series would be impossible without the generous financial support of our Corporate Sponsors:



https://www.antibodysociety.org/

